APO-SALVENT-IPRAVENT STERULES SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE); SALBUTAMOL (SALBUTAMOL SULFATE)

Saatavilla:

APOTEX INC

ATC-koodi:

R03AL02

INN (Kansainvälinen yleisnimi):

SALBUTAMOL AND IPRATROPIUM BROMIDE

Annos:

0.5MG; 2.5MG

Lääkemuoto:

SOLUTION

Koostumus:

IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE MONOHYDRATE) 0.5MG; SALBUTAMOL (SALBUTAMOL SULFATE) 2.5MG

Antoreitti:

INHALATION

Kpl paketissa:

20X2.5ML

Prescription tyyppi:

Prescription

Terapeuttinen alue:

ANTIMUSCARINICS ANTISPASMODICS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0232902001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2005-03-31

Valmisteyhteenveto

Page
1
of
40
PRODUCT MONOGRAPH
PR
APO-SALVENT IPRAVENT STERULES
Salbutamol Sulfate and Ipratropium Bromide Inhalation Solution
Each sterule contains 3 mg salbutamol sulfate [2.5 mg salbutamol base]
and 0.5 mg of
ipratropium bromide anhydrous [as monohydrate] in 2.5 mL of saline
BRONCHODILATOR
APOTEX INC.
DATE OF REVISION:
150 Signet Drive
June 22, 2018
Toronto, Ontario M9L 1T9
Control No. 215519
Page
2
of
40
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION ...............................................................................
3
INDICATIONS AND CLINICAL USE .....................................................................................
3
CONTRAINDICATIONS ..........................................................................................................
3
WARNINGS AND PRECAUTIONS .........................................................................................
4
ADVERSE REACTIONS ...........................................................................................................
8
DRUG INTERACTIONS .........................................................................................................
13
DOSAGE AND ADMINISTRATION .....................................................................................
14
OVERDOSAGE .......................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY ...................................................................
16
STORAGE AND STABILITY .................................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 22
PART II: SCIENTIFIC INFORMATION
...........................................................................
23
PHARMACEUTICAL INFORMATION .................................................................................
23
C